Abstract
Current Medicinal Chemistry - Central Nervous System Agents
Title: Subject Index to Volume 3
Volume: 4 Issue: 1
Author(s): Bentham Science Publishers
Affiliation:
Abstract:
Export Options
About this article
Cite this article as:
Bentham Science Publishers , Subject Index to Volume 3, Current Medicinal Chemistry - Central Nervous System Agents 2004; 4 (1) . https://dx.doi.org/10.2174/1568015043477612
DOI https://dx.doi.org/10.2174/1568015043477612 |
Print ISSN 1568-0150 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6158 |
9
Related Articles
-
Endocannabinoid Signaling in Midbrain Dopamine Neurons: More than Physiology?
Current Neuropharmacology New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Current Psychopharmacology An Introduction to the Nutrition and Metabolism of Choline
Central Nervous System Agents in Medicinal Chemistry Wnt Signaling Pathway in Schizophrenia
CNS & Neurological Disorders - Drug Targets The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets Organometallic Complexes: New Tools for Chemotherapy
Current Medicinal Chemistry Heteromerization of G Protein-Coupled Receptors: Relevance to Neurological Disorders and Neurotherapeutics
CNS & Neurological Disorders - Drug Targets Parkinsons Disease: Genetics and Beyond
Current Neuropharmacology A Comparison Between Quetiapine and Aripiprazole for Treatment of Schizophrenia: A Double Blind Contrast
Current Psychopharmacology A Laconic Overview on Fast Dissolving Sublingual Films as Propitious Dosage Form
Drug Delivery Letters Safety and Efficacy of Levetiracetam for the Management of Levodopa- Induced Dyskinesia in Patients with Parkinson’s Disease: A Systematic Review
CNS & Neurological Disorders - Drug Targets Freezing of Gait in Parkinsonism and its Potential Drug Treatment
Current Neuropharmacology Receptor Heteromers in Parkinson’s Disease and L-DOPA-Induced Dyskinesia
CNS & Neurological Disorders - Drug Targets Therapeutic Strategy of Targeting Astrocytes for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design N-Acetylcysteine for the Treatment of Obsessive-Compulsive Disorder
Current Psychiatry Reviews Revisiting the Medical Management of Parkinson’s Disease: Levodopa versus Dopamine Agonist
Current Neuropharmacology Catatonia Due to a General Medical Condition (Organic Catatonia)
Current Psychiatry Reviews Machine Learning Approaches in Parkinson’s Disease
Current Medicinal Chemistry Genetic Variants in Diseases of the Extrapyramidal System
Current Genomics The Role and Impact of SNPs in Pharmacogenomics and Personalized Medicine
Current Drug Metabolism